186 related articles for article (PubMed ID: 24866329)
21. Effects of changeover from voglibose to acarbose on postprandial triglycerides in type 2 diabetes mellitus patients.
Matsumura M; Monden T; Miyashita Y; Kawagoe Y; Shimizu H; Nakatani Y; Domeki N; Yanagi K; Ikeda S; Kasai K
Adv Ther; 2009 Jun; 26(6):660-6. PubMed ID: 19568704
[TBL] [Abstract][Full Text] [Related]
22. A comparative study of the effects of a dipeptidyl peptidase-IV inhibitor and sulfonylurea on glucose variability in patients with type 2 diabetes with inadequate glycemic control on metformin.
Kim HS; Shin JA; Lee SH; Kim ES; Cho JH; Son HY; Yoon KH
Diabetes Technol Ther; 2013 Oct; 15(10):810-6. PubMed ID: 24050737
[TBL] [Abstract][Full Text] [Related]
23. Acarbose Add-on Therapy in Patients with Type 2 Diabetes Mellitus with Metformin and Sitagliptin Failure: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study.
Yang HK; Lee SH; Shin J; Choi YH; Ahn YB; Lee BW; Rhee EJ; Min KW; Yoon KH
Diabetes Metab J; 2019 Jun; 43(3):287-301. PubMed ID: 30604599
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind trial.
Iwamoto Y; Tajima N; Kadowaki T; Nonaka K; Taniguchi T; Nishii M; Arjona Ferreira JC; Amatruda JM
Diabetes Obes Metab; 2010 Jul; 12(7):613-22. PubMed ID: 20590736
[TBL] [Abstract][Full Text] [Related]
25. Continuous glucose profiles with vildagliptin versus sitagliptin in add-on to metformin: results from the randomized Optima study.
Guerci B; Monnier L; Serusclat P; Petit C; Valensi P; Huet D; Raccah D; Colette C; Quéré S; Dejager S
Diabetes Metab; 2012 Oct; 38(4):359-66. PubMed ID: 22809630
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor gemigliptin compared with sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.
Rhee EJ; Lee WY; Min KW; Shivane VK; Sosale AR; Jang HC; Chung CH; Nam-Goong IS; Kim JA; Kim SW;
Diabetes Obes Metab; 2013 Jun; 15(6):523-30. PubMed ID: 23320436
[TBL] [Abstract][Full Text] [Related]
27. Cotreatment with the α-glucosidase inhibitor miglitol and DPP-4 inhibitor sitagliptin improves glycemic control and reduces the expressions of CVD risk factors in type 2 diabetic Japanese patients.
Imai C; Saito M; Mochizuki K; Fuchigami M; Goda T; Osonoi T
Metabolism; 2014 Jun; 63(6):746-53. PubMed ID: 24559582
[TBL] [Abstract][Full Text] [Related]
28. A prospective, randomized, multicenter trial comparing the efficacy and safety of the concurrent use of long-acting insulin with mitiglinide or voglibose in patients with type 2 diabetes.
Son JW; Lee IK; Woo JT; Baik SH; Jang HC; Lee KW; Cha BS; Sung YA; Park TS; Yoo SJ; Yoon KH
Endocr J; 2015; 62(12):1049-57. PubMed ID: 26411328
[TBL] [Abstract][Full Text] [Related]
29. Effect of sitagliptin on glycemic control and beta cell function in Japanese patients given basal-supported oral therapy for type 2 diabetes.
Asai S; Ohta A; Kato H; Sada Y; Nagai Y; Kondo A; Sasaoka T; Tanaka Y
Endocr J; 2014; 61(12):1213-20. PubMed ID: 25231694
[TBL] [Abstract][Full Text] [Related]
30. Glycated albumin (GA) is more advantageous than hemoglobin A1c for evaluating the efficacy of sitagliptin in achieving glycemic control in patients with type 2 diabetes.
Shima K; Komatsu M; Noma Y; Miya K
Intern Med; 2014; 53(8):829-35. PubMed ID: 24739602
[TBL] [Abstract][Full Text] [Related]
31. Add-on therapy with the DPP-4 inhibitor sitagliptin improves glycemic control in insulin-treated Japanese patients with type 2 diabetes mellitus.
Katsuno T; Ikeda H; Ida K; Miyagawa J; Namba M
Endocr J; 2013; 60(6):733-42. PubMed ID: 23386390
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of voglibose in comparison with acarbose in type 2 diabetic patients.
Vichayanrat A; Ploybutr S; Tunlakit M; Watanakejorn P
Diabetes Res Clin Pract; 2002 Feb; 55(2):99-103. PubMed ID: 11796175
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of sitagliptin as add-on therapy on glycemic control and blood glucose fluctuation in Japanese type 2 diabetes subjects ongoing with multiple daily insulin injections therapy.
Shimoda S; Iwashita S; Ichimori S; Matsuo Y; Goto R; Maeda T; Matsuo T; Sekigami T; Kawashima J; Kondo T; Matsumura T; Motoshima H; Furukawa N; Nishida K; Araki E
Endocr J; 2013; 60(10):1207-14. PubMed ID: 23912974
[TBL] [Abstract][Full Text] [Related]
34. Switching α-glucosidase inhibitors to miglitol reduced glucose fluctuations and circulating cardiovascular disease risk factors in type 2 diabetic Japanese patients.
Hariya N; Mochizuki K; Inoue S; Saito M; Fuchigami M; Goda T; Osonoi T
Drugs R D; 2014 Sep; 14(3):177-84. PubMed ID: 25079671
[TBL] [Abstract][Full Text] [Related]
35. Comparison of acarbose and voglibose in diabetes patients who are inadequately controlled with basal insulin treatment: randomized, parallel, open-label, active-controlled study.
Lee MY; Choi DS; Lee MK; Lee HW; Park TS; Kim DM; Chung CH; Kim DK; Kim IJ; Jang HC; Park YS; Kwon HS; Lee SH; Shin HK
J Korean Med Sci; 2014 Jan; 29(1):90-7. PubMed ID: 24431911
[TBL] [Abstract][Full Text] [Related]
36. Enhancement of postprandial endogenous insulin secretion rather than exogenous insulin injection ameliorated insulin antibody-induced unstable diabetes: a case report.
Kaneko K; Satake C; Izumi T; Tanaka M; Yamamoto J; Asai Y; Sawada S; Imai J; Yamada T; Katagiri H
BMC Endocr Disord; 2019 Jan; 19(1):5. PubMed ID: 30621663
[TBL] [Abstract][Full Text] [Related]
37. Cross-Over Study Comparing Postprandial Glycemic Increase After Addition of a Fixed-Dose Mitiglinide/Voglibose Combination or a Dipeptidyl Peptidase-4 Inhibitor to Basal Insulin Therapy in Patients with Type 2 Diabetes Mellitus.
Ihana-Sugiyama N; Yamamoto-Honda R; Sugiyama T; Tsujimoto T; Kakei M; Noda M
Med Sci Monit Basic Res; 2017 Feb; 23():36-44. PubMed ID: 28242866
[TBL] [Abstract][Full Text] [Related]
38. Effects of once-daily sitagliptin on 24-h glucose control following 4 weeks of treatment in Japanese patients with type 2 diabetes mellitus.
Nonaka K; Tsubouchi H; Okuyama K; Fukao Y; Johnson-Levonas AO; Amatruda JM
Horm Metab Res; 2009 Mar; 41(3):232-7. PubMed ID: 19253204
[TBL] [Abstract][Full Text] [Related]
39. Effects of mitiglinide, a short-acting insulin secretagogue, on daily glycemic variability and oxidative stress markers in Japanese patients with type 2 diabetes mellitus.
Kodani N; Saisho Y; Tanaka K; Kawai T; Itoh H
Clin Drug Investig; 2013 Aug; 33(8):563-70. PubMed ID: 23797928
[TBL] [Abstract][Full Text] [Related]
40. Therapeutic efficacy of mitiglinide combined with once daily insulin glargine after switching from multiple daily insulin regimen of aspart insulin and glargine in patients with type 2 diabetes mellitus.
Yoshihara T; Kumashiro N; Kanazawa Y; Mita T; Sakurai Y; Kawai J; Abe M; Motojima K; Hara K; Yamazaki Y; Kanazawa A; Miwa S; Sato F; Kanno R; Shimizu T; Sakai K; Uchino H; Watada H; Tanaka Y; Kawamori R; Hirose T
Endocr J; 2006 Feb; 53(1):67-72. PubMed ID: 16543674
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
